Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 496-502 , November 2006

E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients

  • He-Cheng Li, M.D., Ph.D.

      Affiliations

    • Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Jeffrey M. Albert, B.S.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Eric T. Shinohara, M.D.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Qiuyin Cai, M.D., Ph.D.

      Affiliations

    • Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Andrea Freyer, B.S.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Hui Cai, M.D., Ph.D.

      Affiliations

    • Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Carolyn Cao, M.S.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Zuofei Wang, M.D.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Nobuhiko Kataoka, M.D., Ph.D.

      Affiliations

    • Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Ming Teng, M.D.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Wei Zheng, M.D., Ph.D.

      Affiliations

    • Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • Bo Lu, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-615-343-9233; fax: +1-615-343-0161.

Received 8 September 2005 ,Revised 8 February 2006 ,Accepted 9 February 2006.

References 

  1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988;41:184–197
  2. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000 (The global picture). Eur J Cancer. 2001;37(Suppl 8):S4–S66
  4. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality (Part I: International comparisons). BJU Int. 2002;90:162–173
  5. Bostwick DG, Graham SD, Napalkov P, et al. Staging of early prostate cancer: A proposed tumor volume-based prognostic index. Urology. 1993;41:403–411
  6. Zhou WN, Chen ZP, You C, et al. Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma. Ai Zheng. 2004;23(Suppl 11):1555–1560[in Chinese]
  7. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99–108
  8. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 2005;107:155–176
  9. Vleminckx K, Vakaet L, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–119
  10. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992;52:5104–5109
  11. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994;54:3929–3933
  12. Li LC, Chui RM, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873–876
  13. Shin Y, Kim IJ, Kang HC, et al. The E-cadherin −347G->GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis. 2004;25:895–899
  14. Tsukino H, Kuroda Y, Imai H, et al. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int. 2004;72:203–207
  15. Verhage BA, van Houwelingen K, Ruijter TE, et al. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer. 2002;100:683–685
  16. Shin Y, Kim IJ, Kang HC, et al. A functional polymorphism (−347 G->GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis. 2004;25:2173–2176
  17. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed.. New York (NY): Springer; 2002;p. 309–316Prostate.
  18. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208:1–33
  19. Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524–6536
  20. Wu MS, Huang SP, Chang YT, et al. Association of the -160 C –> a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer. 2002;94:1443–1448
  21. Lei H, Sjoberg-Margolin S, Salahshor S, et al. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer. 2002;98:199–204
  22. Pharoah PD, Oliveira C, Machado JC, et al. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer. 2002;101:196–197
  23. Humar B, Graziano F, Cascinu S, et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 2002;21:8192–8195
  24. Porter TR, Richards FM, Houlston RS, et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 2002;21:1928–1933
  25. Tsukino H, Kuroda Y, Nakao H, et al. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett. 2003;195:53–58
  26. Zhang X, Ma X, Zhu QG, et al. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol. 2003;170:1379–1382
  27. Nakamura A, Shimazaki T, Kaneko K, et al. Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res. 2002;502:19–24

☆ This work was supported by DOD PC031161 to B.L., RO1CA90899 to W.Z., and UICC fellowship ICRETT1025 to H.C.L.

PII: S1078-1439(06)00062-7

doi: 10.1016/j.urolonc.2006.02.018

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 496-502 , November 2006

Article Tools

* Image Usage & Resolution